Trial Profile
Phase Ib Trial of CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions Delivered With the Surefire Infusion System (SIS) for CEA-Expressing Liver Metastases or Pancreas Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Oct 2021
Price :
$35
*
At a glance
- Drugs Anti CEA CAR T cell therapy Sorrento Therapeutics (Primary)
- Indications Adenocarcinoma; Liver metastases; Pancreatic cancer
- Focus Adverse reactions
- Acronyms HITM-SURE
- 20 Oct 2021 Status changed from active, no longer recruiting to completed.
- 29 Oct 2020 Planned End Date changed from 1 Aug 2020 to 1 Feb 2021.
- 10 Mar 2020 Planned End Date changed from 1 Dec 2019 to 1 Aug 2020.